Product Proposed Indication Development Stage

Bendamustine RTD
30 or 60 minutes IV infusion in 500 mL admixture

  • Chronic lymphocytic leukemia (CLL)
  • Indolent B-cell non-Hodgkin’s lymphoma (NHL)

NDA tentatively approved in July 2014

RYANODEX®
(dantrolene sodium) for injectable suspension

  • Exertional heat stroke (EHS)

Phase 2
FDA ODD granted
Fast Track Designation

Pemetrexed
liquid version of Alimta®

  • Locally advanced or metastatic nonsquamous non-small cell lung cancer
  • Mesothelioma

Pre-clinical

IV=intravenous; RTD=ready-to-dilute; RTU=ready-to-use; ODD=orphan drug designation.
Alimta® is a registered trademark of Eli Lily and Company.

Oncology

Ready-to-Dilute (RTD) Bendamustine Hydrochloride

Eagle RTD bendamustine hydrochloride (HCl) is a ready-to-dilute liquid in a multi-dose vial being developed to provide extended drug stability over other bendamustine HCl liquid products for use with a 500 mL IV bag.

Proposed Indication

Chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL)

Pemetrexed

Eagle pemetrexed is designed to be a ready-to-dilute (RTD) liquid of 500 mg in a multi-dose vial.

Proposed Indication

Eagle pemetrexed is being developed for the treatment of locally advanced or metastatic non-small cell lung cancer and mesothelioma.

Critical Care

RYANODEX® (dantrolene sodium) for injectable suspension will be further developed for additional indications.

RYANODEX® is a vial containing 250 mg of dantrolene sodium in lyophilized powder form for injectable suspension. It requires 5 mL of sterile water for reconstitution.9

Proposed Indication

RYANODEX® is being evaluated for the treatment of exertional heatstroke in conjunction with appropriate supportive measures.